Pfizer Inc announced it will globally withdraw all dalbavancin marketing applications for the treatment of complicated skin and skin structure infections in adults, including the U.S. new drug application (NDA) and the European marketing authorization application (MAA). ... more
Tags: marketing, skin, application, applications, pfizer, dalbavancin, withdraw,

Keywords: Dermatology news, medical news, health news, medical headlines, healthcare news, health articles, medicine articles, welfare, living

Description: Pfizer Inc announced it will globally withdraw all dalbavancin marketing applications for the treatment of complicated skin and skin structure infections in adults, including the U.S. new drug app